Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Awarding ceremonies to be held on June 10, 2025, at the 16th Annual IMWG Summit in Milano, ItalyMILAN, June 10, 2025 (GLOBE ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for HR-positive, HER2-negative metastatic breast cancer that also has one or ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

KRAKOW, Poland I June 12, 2025 I Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that ...

Such a cobblestone tongue is a telltale sign of a rare genetic condition called Cowden syndrome. It's caused by inherited ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...